Analysts Set Expectations for TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Tango Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings per share of ($1.39) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

TNGX has been the subject of a number of other reports. Guggenheim cut their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Friday, November 8th. Finally, B. Riley dropped their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.14.

Tango Therapeutics Stock Performance

NASDAQ:TNGX opened at $3.08 on Wednesday. The stock has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $6.60. The firm has a market capitalization of $330.85 million, a PE ratio of -2.61 and a beta of 0.81. Tango Therapeutics has a 52-week low of $2.59 and a 52-week high of $13.01.

Insider Buying and Selling

In related news, insider Boxer Capital Management, Llc sold 3,080,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $3.14, for a total transaction of $9,671,200.00. Following the completion of the transaction, the insider now directly owns 3,610,642 shares of the company’s stock, valued at approximately $11,337,415.88. This represents a 46.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mace Rothenberg acquired 10,000 shares of Tango Therapeutics stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $3.78 per share, for a total transaction of $37,800.00. Following the purchase, the director now owns 31,250 shares in the company, valued at approximately $118,125. The trade was a 47.06 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 6.30% of the stock is owned by company insiders.

Institutional Trading of Tango Therapeutics

Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in Tango Therapeutics by 42.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares during the period. Point72 DIFC Ltd bought a new position in Tango Therapeutics during the second quarter valued at $54,000. The Manufacturers Life Insurance Company raised its stake in shares of Tango Therapeutics by 8.1% in the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock valued at $253,000 after acquiring an additional 2,218 shares during the period. Susquehanna Fundamental Investments LLC lifted its holdings in shares of Tango Therapeutics by 82.2% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 62,417 shares of the company’s stock worth $536,000 after acquiring an additional 28,155 shares during the last quarter. Finally, Quarry LP bought a new position in Tango Therapeutics during the 2nd quarter valued at about $99,000. 78.99% of the stock is currently owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.